- About Us
- Our Programs
- Our Events
- uCity Square
- Support Us
Incubating successful startups means more than giving them a space to grow
Finding flexible and affordable space can be an important step in the formation and growth of a successful company. Equally important is being located in an environment with a “critical mass” of entrepreneurs, innovators and sources of capital. Our world-class Port business incubator is one of only a handful of incubators in the region offering turnkey office and lab facilities, as well as access to shared lab equipment that is often too expensive for an early-stage company to purchase on its own. Beyond the physical infrastructure, the Port offers a strong connection to Greater Philadelphia’s innovation ecosystem and the ingredients startups need to grow and be successful. Residents can access Science Center networks and programs to capitalize and develop their businesses, while tapping into the rich pool of local talent to grow their workforce.
Gabriel Otte, CEO and co-founder, Freenome - graduate of the Port business incubator
Home to a diverse group of early-stage companies in life sciences and emerging technologies, the Port business incubator at the Science Center in Philadelphia is often a startup’s first stop on its path to growth. Our residents are shaping the future of healthcare, energy, technology and beyond.
3711 Partners LLC is a data science company developing cutting edge algorithms to analyze large and complex data. We provide data consulting services and custom algorithm development to a wide variety of clients from financial institutions to airport operators.
ANGLE North America
A medical technology company with a device that rapidly separates rare cells, such as cancer cells, from blood, for early diagnosis.
AUM Life Tech
A biotech startup developing gene-targeting molecules that can be used for research and personalized medicine for a variety of rare diseases, cancers, and infectious diseases.
Delivers high-quality medical communications for healthcare providers and patients. Bioscript brings expertise, clarity and value to medical publications, meetings, electronic media and educational events.
Improving quality of healthcare through the use an automated interpretation technology, based on machine learning algorithms. Their decision-support tool, AutoEEG, integrates into neurologists’ clinical workflow and provides real-time seizure detection alerts.
Developing a novel protein replacement strategy for treating mitochondrial diseases in patients. This technology will have broad application, should the company be successful in demonstrating activity in treating Friedreich’s Ataxia - a rare debilitating condition in which children and young adults progressively lose the ability to walk and speak as their hearts grow thick and weak before they eventually fail.
Developing first-in-class precision methodologies that translate evidence based science into clinical applications. Their technologies have enabled breakthrough products that are transforming the landscapes of medicine through pioneering work in clinical research utilizing complex molecular and cell biological systems.
Developing a blood test for the rapid diagnosis of epilepsy. This blood test differentiates
epilepsy from other causes of seizures, sparing patients from unnecessary tests and inappropriate treatments.
A consulting and medical device development company addressing undesirable immune responses to protein-based therapies.
Developing drugs to treat and prevent Parkinson’s disease by removing the alpha-synuclein protein from nerve cells in the gut.
Specializing in the research, development and marketing of novel nutritional supplements. The company’s initial product, Bone Marrow Smart™, is the first supplement intended to support bone marrow health.
Offers assays and testing kits for research and drug discovery in cancer and other major diseases. The technology platform seamlessly combines experimental validation with quantitation of specific molecules, simplifying the process of new target discovery.
Fermentec’s technology, the microdroplet maker, is to produce beer faster. With our product, companies will be able to expedite the process of fermentation of beer by three to nine times.
A world-leading developer of graphene sensors and electronics. Their innovative manufacturing process makes it economically viable to produce large area graphene for commercial and industrial applications.
Establishing a next-generation nanotechnology drug delivery system that will reduce drug side effects and increase patient compliance. Hyalo accomplishes this by target-specific drug delivery, time-controlled drug release, sequential drug delivery intelligence and 100% biodegradability.
Advancing a pipeline of cancer immunotherapy candidates designed to work by stimulating the body’s immune system. Immunome’s proprietary RealMAb™ technology enables the simultaneous discovery of novel cancer antigens, molecules that cause the immune system to produce antibodies, and the native human antibodies that target those antigens and neutralize them.
Creates opportunities for low-income students by increasing their interest and exposure to Science, Technology, Engineering, and Mathematics (STEM) disciplines through inquiry- and project-based learning.
Provides innovative medical imaging solutions for multisite clinical trials and telemedicine. Headquartered in France, Keosys has become a European leader in Imaging Data Management Systems and advanced medical imaging software.
Lenima Field Diagnostic
Creating a point-of–care diagnostic test for infectious diseases in the gastrointestinal tract, blood stream, and respiratory tract. The test menu also includes novel cancer markers for screening high-risk individuals.
Developing a small molecule therapy to reduce side effects and increase effectiveness of radiation treatment for cancer. Synthesized from natural flaxseed, it has been shown to enhance chemotherapy and radiation treatment while protecting normal tissue from damage.
Developing a first-in-class small molecule cancer therapy. Targeting the most potent suppressor pathways in human cancer, its lead drug candidate, ONC201, is in clinical trials for multiple cancer indications.
Developing a revolutionary 3-D printing process that offers increased speed, superior variety of compatible materials, smoother surface finishes, and greater degree of detail than currently available.
Persistent Telecom Solutions
Developing and offering products and services for network service providers to manage network performance, service and reporting, and to predict faults and service level breaches.
Helps companies develop brands that symbolize the values and ideals espoused by their target consumers. Driven by robust data analytics, the client brand comes to represent an identity that customers aspire to represent themselves.
Developing first-in-class protease inhibitors based on a platform that mimics natural structures. Initial targets include antiviral therapies for SARS, MERS and Ebola. Future platform expansions are planned to address cardiac and brain disorders.
Leading the effort to translate the latest gene delivery research into therapeutic applications for diseases where there is serious unmet need. PhenGen Biotech is developing novel therapeutics and research tools based on rAAV (recombinant adeno-associated viral) vectors.
Offers advanced body-wide quantification of medical images for applications in radiology, radiation oncology, and medical oncology. Its unique Automatic Anatomy Recognition (AAR) system supports recognition and delineation of anatomical objects and diseased tissue in multiple body regions in MRI, CT, and PET/CT images.
A subsidiary of the UK-based Royal Society of Chemistry, the company's main purpose is to help promote chemical science activities in North America.
Generates protein particles that contain DNA to be delivered to cells with genetic defects, which could potentially correct the defects.
Working to address a significant gap in care for chemotherapy patients. Sanguis is developing a convenient and cost-efficient handheld device for frequent monitoring of blood cell counts in these patients. With the device, patients receiving chemotherapy can monitor their side-effects while preventing serious medical complications.
Developing novel microscope cover slides with embedded microspheres to improve resolution. This method is considerably less expensive than adding a high-resolution optical lens to an existing microscope, or purchasing a super-resolution imaging microscope.
A marketing strategy and implementation company serving small- and medium-sized businesses and non-profit organizations. Specialties include tourism, economic development, higher education and start-ups.
Developing a small molecule therapy that inhibits the metabolic process in cancer cells to treat patients with solid tumors such as pancreatic cancer.
A biotech startup whose primary mission is to discover and develop small molecule therapeutics to treat chronic viral infections and its associated diseases, including cancer and autoimmunity. Its secondary mission is to exploit viral latency to develop improved vectors for gene therapy and vaccine purposes.
Developing next-generation oncology therapeutics utilizing a proprietary Targeted Protein Therapeutic technology (TPT). The company’s novel TPTs have been designed to overcome the efficacy and safety challenges of existing antibody-drug conjugates.
International companies can take advantage of the Global Soft Landing Program, which leverages the assets and resources of the Science Center and Greater Philadelphia’s entrepreneurial community to help global companies establish a foothold in the region’s life sciences and technology markets. Philadelphia offers a strategic location within easy reach of the nation’s regulatory/legislative hub in Washington and its financial center in New York.
Dawn Flitcraft, COO, Keosys NA
The International Business Innovation Association has designated the Port incubator as an InBIA Soft Landings International Incubator. The InBIA’s Soft Landings Program recognizes incubators that are especially capable of helping nondomestic companies enter the incubator’s domestic market. The Port is one of only 27 business incubation programs from around the world that have earned the designation since InBIA began the program in 2005.
The Science Center has formed partnerships with a number of international programs. For example, a partnership with Switzerland’s Yverdon Technology Park gives participating entrepreneurs space in the Port and Y-PARC’s incubator, as well as personalized support services, cultural coaching and counseling, and logistical support for travel and accommodation. This type of “foreign exchange,” organized through the Global Soft Landing Program helps international companies ease the transition when establishing operations in the reciprocal region and incubator.
The Science Center has partnerships with:
The Port is a turn-key facility catering to the flexible leasing needs of startup companies. Residents may select from a combination of fully furnished offices, cubicles, and wet and dry labs. Port staff leverages established networks to identify area resources that can help resident companies to grow and flourish.
All-inclusive with the Port’s easy-to-manage fee are: